Numerical descriptors for the characterization of chiral compounds and their applications in modeling biological and toxicological activities

Current Topics in Medicinal Chemistry

Volumn 11, Issue 7, 2011, Pages 771-787

  Natarajan, Ramanathan ^a   Basak, Subhash C ^b  

^a Centre for Mathematical Sciences   (India)

^b UNIVERSITY OF MINNESOTA DULUTH   (United States)

Author keywords

Chirality; Chirality index; Chirality measures; Diastereoisomers; Enantiomers; Quantitative structure activity relationship

Indexed keywords

ARTICLE; CHIRALITY; DIASTEREOISOMER; ENANTIOMER; MATHEMATICAL MODEL; STEREOCHEMISTRY; STEREOISOMERISM; STEREOSPECIFICITY;

DRUG DESIGN; ECOTOXICOLOGY; HUMANS; MOLECULAR CONFORMATION; PESTICIDES; PHARMACEUTICAL PREPARATIONS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; QUANTUM THEORY; STEREOISOMERISM;

EID: 79953669526     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802611795165197     Document Type: Article

References (136)

1. Kelvin, L. Baltimore Lectures on Molecular Dynamics and the Wave Theory of Light, C.J. Clay and Sons, Cambridge University Press Warehouse: London, 1904.
2. Pasteur, L. Two lectures delivered to the Société Chimique de Paris, Jan. 20 & Feb. 3, 1860.
3. van't Hoff, J.H. Sur les formules de structure dans l'espace. Bull. Soc. Chim. France, 1875, 23, 295-301
4. The original Dutch paper was published in 1874, van 't Hoff, J.H. Sur les formules de structure dans l'espace. Arch. Neerl. Sci. Exactes Nat., 1874, 9, 445-454.
5. Le Bel, J.A. Sur des relations qui existent entre les formules atomiques des corps organiques et le pouvoir rotatoire de leurs dissolutions. Bull. Soc. Chim. France, 1874, 22, 337-347
6. English translation is available in Richardson G.M. In: Classics in Theory of Chemical Combinations, Benfey, O.T, Ed.; New York: Dover publications, 1963, pp.161-171.
7. Eliel, E.L.; Wilen, S.H. Stereochemistry of Organic Compounds, Wiley: New York, 1994.
8. Eliel, E.L. Stereochemistry of Carbon Compounds, McGraw-Hill: New York, 1962.
9. Cahn, R.S.; Ingold, C.K.; Prelog, V. The specification of asymmetric configuration in organic chemistry. Experientia, 1956, 12, 81-124. http://accelrys.com/products/discovery-studio/Chem3DUltra:www.cambridgesoft.comACD/Chemsketch:http://www.acdlabs.com
10. Rouhi, A.M. Extraterrestrial: How to Detect Enantioenrichment on Saturn's Moon Titan. Chem. Eng. News, 2002, 80, 56-57.
11. Fraser, R. R. In Asymmetric Synthesis; Morrison, J. D., Ed.; Academic Press: New York, 1983, Vol. 1, Chapter 9, p. 173.
12. Methods in Stereochemical Analysis; Morrill, T. C., Ed.; VCH Publishers Inc.: New York, 1986, Vol. 5.
13. Weisman, G. R. In: Asymmetric Synthesis; Morrison, J. D., Ed.; Academic Press: New York, 1983, Vol. 1, Chapter 8, p. 153.
14. Pirkle, W. H.; Hoover, D. J. Top. Stereochem., 1982, 13, 263.
15. Yamaguchi, S. In: Asymmetric Synthesis; Morrison, J. D. Ed.;Academic Press: NewYork, 1983, Vol. 91, Chapter 7, p. 125.
16. Parker, D. NMR Determination of enantiomeric purity. Chem. Rev., 1991, 91, 1441-1457.
17. nd ed. Advanced Separation Technologies, Inc.: Whippany, NJ, 1999.
18. Silverstein, R.M. Chirality in insect communication. J. Chem. Ecol., 1998, 14, 1981-2004.
19. Joris, J.; Costello, A.; Dubner, R.; Hargreaves, K.H. Opiates suppress carrageenan-induced edema and hyperthermia at doses that inhibit hyperalgesia. Pain, 1990, 43, 95-103.
20. Goldstein, A.; Lowney, L.I.; Pal, B.K. Stereospecific and nonspecific interactions of the morphine congener levorphanol in subcel-lular fractions of mouse brain. Proc. Natl. Acad. Sci. USA, 1971, 68, 1742-1747.
21. Leffingwell, J.C. Chirality and Bioactivity I: Pharmacology. Leffingwell Reports, 3 (No.1), 2003, 1-27. www.leffingwell.com
22. Ito, T.; Ando, H.; Suzuki, T.; Ogura, T.; Hotta, K.; Imamura, Y.; Yamaguchi, Y.; Handa, H. Identification of primary target of tha-lidomide teratogenicity. Science, 2010, 327, 1345-1350.
23. Everts, S. Unraveling thalidomide's tragic effects. Chem. Eng. News, 2010, 88(11), 9.
24. Ariens, E.J. Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology. Eur. J. Clin. Pharmacol., 1984, 26, 663-668.
25. Ariens, E. J. Racemic therapeutics - ethical and regulatory aspects. Eur. J. Clin. Pharmacol., 1991, 41, 89-93.
26. Ariens, E.J. In: Drug Design and Synthesis. C. Brown, Ed.; Academic Press: New York, 1990, pp. 29-43.
27. Eriksson, T.; Bjorkman, S.; Roth, B.; Fyge, A.; Hoglund, P. Stereo-specific determination, chiral inversion in vitro and pharmacokinet-ics in humans of the enantiomers of thalidomide. Chirality, 1995, 7, 44-52.
28. Thayer, A. M. Centering on chirality. Chem. Eng. News., August 6, 2007, www.cen-online.org
29. Kurihara, N.; Miyamoto, J. Ed.; Chirality in Agrochemicals, Wiley Series in Agrochemicals and Plant Protection, Wiley: New York, 1998.
30. Liu, W.; Ye, J.; Jin, M. Enantioselective phytoeeffects of chiral pesticides. J. Agric. Food Chem., 2009, 57, 2087-2095.
31. Ali, I.; Aboul-Enein, H.Y. Chiral Pollutants: Distribution, Toxicity and Analysis by Chromatography and Capillary Electrophoresis, John Wiley & Sons, Chichester, England, 2004.
32. Müller, T.A; Kohler, H.-P.E. Chirality of pollutants-effects on metabolism and fate. Appl. Microbiol. Biotechnol., 2004, 64, 300-316.
33. Caner, H.; Groner, E.; Levy, L.; Agranat, I. Trends in the development of chiral drugs. Drug Discov. Today, 2004, 9(3), 105-110.
34. Lipkowitz, K.B.; D'Hue, C.A.; Sakamoto, T.; Stack, J.N. Stereocar-tography: A computational mapping technique that can locate regions of maximum stereoinduction around chiral catalyst. J. Am. Chem. Soc., 2002, 124, 14255-14267.
35. Stinson, S.C. Counting on Chirality. Chem. Eng. News, 1998, 76 (38), 83-104
36. Stinson, S.C. Chiral drug interactions. Chem. Eng. News, 1999, 77(41), 101-120
37. Stinson, S.C. Chiral drugs. Chem. Eng. News, 2000, 78(43), 55-78
38. Stinson, S.C. Chiral pharmaceuticals. Chem. Eng. News, 2001, 79(40), 79-97
39. Buda, A. B.; Heyde, T.A.D.; Mislow, K. On quantifying chirality. Angew. Chem. Int. Ed., 1992, 31, 989-1007.
40. Weinberg, N.; Mislow, K. A Unification of chirality measures. J. Math. Chem., 1995, 17, 35-53.
41. Petitjean, M. Chirality and symmetry measures: A transdisciplinary review. Entropy, 2003, 5, 271-312.
42. Crippen, G.M. Chirality descriptors in QSAR. Curr. Comput. Aided Drug Des., 2008, 4, 259-265
43. Natarajan, R.; Basak, S.C. Numerical characterization of molecular chirality of organic compounds, Curr. Comput. Aided Drug Des., 2009, 5, 1-12.
44. Guye, P. A. Influence de la constitution chimique des dérivés du carbone sur le seng et les variations de leur pouvoir rotatoire. Compt. Rend. Hebdom. Acad. Sci., 1890, 110, 714-716.
45. R uch, E.; Schönhofer, A.; Ugi, I. Die Vandermondesche determi-nante als näherungsansatz für eine chiralitätsbeobachtung, Ihre verwendung in der stereochemie und zur berechnung der optischen aktivität. Thoer. Chim. Acta, 1967, 7, 420-432.
46. Ruch, E. and Schönhofer, A. Theorie der chiralitätsfunktionen. Theor. Chim. Acta, 1970, 19, 287-294.
47. Ruch, E. Algebraic aspects of chirality phenomenon in chemistry. Acct. Chem. Res., 1968, 5, 49-56.
48. Rassat, A. Un critere de classement des systemes chiraux de points a partir de la distance au sens de haussdorf. Compt. Rend. Hebdom. Acad. Sci. Paris (série II), 1984, 299, 53-55.
49. Mezey, P.G. The degree of similarity of three-dimensional bodies: Application to molecular shape analysis. J. Math. Chem., 1991, 7, 39-49.
50. Mezey, P.G. Similarity analysis in two and three-dimensions using lattice animals and polycubes. J. Math. Chem., 1992, 11, 27-45.
51. Mezey, P.G.; Ponec, R.; Amat, L; Carbo-Dorca, R. Quantum similarity approach to the characterization of molecular chirality. Enan-tiomer, 1999, 4, 371-378.
52. Mezey, P.G. The proof of the metric properties of a fuzzy chirality measure of molecular electron density clouds. J. Mol. Struct., (THEOCHEM), 1998, 455, 183-190.
53. Mezey PG. Generalized chirality and symmetry deficiency. J. Math. Chem., 1998, 23, 65-84.
54. Grimme, S. Continuous symmetry measures for electronic wave-functions. Chem. Phys. Lett., 1998, 297, 15-22.
55. Luzanov, A.V.; Babich, E.N. Electronic and topological chirality indexes for dissymmetric molecular systems. Struct. Chem., 1992, 3, 175-181
56. Luzanov, A.V.; Babich, E.N. Quantum-chemical quantification of molecular complexity and chirality. J. Mol Srtuct., (THEOCHEM), 1995, 333, 279-290
57. Luzanov, A.V.; Nerukh, D. Simple one-electron invariants of molecular chirality. J. Math. Chem., 2007, 41, 417-435.
58. Capozziello, S.; Lattanzi, A. Geometric approach to center molecular chirality: A chirality selection rule. Chirality, 2003, 15, 227-230.
59. Capozziello, S.; Lattanzi, A. Algebraic structure of central molecular chirality starting from fischer projections. Chirality, 2003, 15, 466-471.
60. Capozziello, S.; Lattanzi, A. Description of chiral tetrahedral molecule via an aufbau approach. J. Mol. Struct. (THEOCHEM), 2004, 673, 205-209.
61. Zabrodsky, H.; Peleg, S.; Avnir, D. Continuous symmetry measures. J. Am. Chem. Soc., 1992, 114, 7843-7851.
62. Zabrodsky, H.; Avnir, D. Continuous symmetry measures. 4. chir-laity. J. Am. Chem. Soc., 1995, 117, 462-473.
63. Avnir, D.; Hel-Or, H. Z.; Mezey, P. G. Symmetry and Chirality: Continuos Measures. In: The Encyclopedia of Computational Chemistry; Schleyer, P. V. R., Allinger, N. L., Clark, T., Gasteiger, J., Kollman, P. A., Schaefer, H. F., III, Schreiner, P. R., Eds.; Wiley: Chichester, 1998, Vol. 4, pp. 2890-2901.
64. Continuous Symmetry and Chirality Measures: http://www.csm.huji.ac.il/
65. Keinan, S.; Avnir, D. Quantitative chirality in structure-activity correlations. shape recognition by trypsin by the D2 dopamine receptor, and by cholineesterases. J. Am. Chem. Soc, 1998, 120, 6152-6159.
66. Gilat, G. On Quantifying chirality - obstacles and problems towards unification. J. Math. Chem., 1994, 15, 197-205.
67. Basak, S.C.; Natarajan, R.; Nowak, W.; Miszta, P.; Klun, J. A. Three dimensional structure-activity relationships (3D-QSAR) for insect repellency of diastereoisomeric compounds: a hierarchical molecular overlay approach. SAR QSAR Environ. Res., 2007, 18, 237-250
68. Natarajan, R.; Basak, S.C.; Balaban, A.T.; Klun, J.A.; Schmidt, W.F. Chirality index, molecular overlay and the biological activity of diastereoisomeric mosquito repellents. Pest Manag. Sci., 2005, 61, 1193-1201.
69. Seri-Levy, A.; West, S.; Richards, W.G. Molecular similarity, quantitative chirality and QSAR for chiral drugs. J. Med. Chem., 1994, 37. 1727-1732.
70. Seri-Levy, A.; West, S.; Richards, W.G. Chiral drug potency: Pfeif-fer's rule and computed chirality coefficients. Tetrahedron: Asymmetry, 1993, 4, 1917-1923.
71. Benigni, R.; Cotta-Ramusino, M.; Gallo, G.; Giorgi, F.; Giuliani, A.; Varì, M.R. Deriving a quantitative chirality measure from molecular similarity indices. J. Med. Chem., 2000, 43, 3699-3703.
72. Aires-de-Sousa, J.; Gasteiger, J. New description of molecular chirality and its application to the prediction of the preferred enan-tiomer in stereoselective reactions. J. Chem. Inf. Comput. Sci., 2001, 41, 369-375.
73. Aires-de-Sousa, J.; Gasteiger, J.; Gutman, I.; Vidovic, D. I. Chirality codes and molecular structure. J. Chem. Inf. Comput. Sci., 2004, 44, 831-836.
74. Aires-de-Sousa, J.; Gasteiger, J. Prediction of enantiomeric selectivity in chromatography - application of conformation-dependent and conformation-independent descriptors of molecular chirality. J. Mol. Graph. Model, 2002, 20, 373-388.
75. Caetano, S.; Aires-de-Sousa, J.; Daszykowski, A.; Heyden, Y. V. Prediction of enantio selectivity using chirality codes and classification and regression trees. Anal. Chim. Acta, 2005, 544, 315-326.
76. Aires-de-Sousa, J.; Gasteiger, J. Prediction of enantiomeric excess in a combinatorial library of catalytic enantioselective reactions. J. Comb. Chem., 2005, 7, 298-301.
77. Zhang, Q. Y.; Carrera, G. A.; Gomes, M. J. S.; Aires-de-Sousa, J. Automatic assignment of absolute configuration from 1D NMR Data. J. Org. Chem., 2005, 70, 2120-2130. http://www2.ccc.uni-erlangen.de/software/petra/ http://www.molecular-networks.com/
78. Zhang, Q.-Y.; Aires-de-Sousa, J. New description of molecular chirality and its application to the prediction of the preferred enan-tiomer in stereoselective reactions. J. Chem. Inf. Model, 2006, 46, 2278-2287.
79. Diaz, H.G.; Sánchez, I.H.; Uriarte, E.; Santana, L. Symmetry considerations in markovian chemicals 'in silico' design (MARCH-INSIDE) I: Central chirality codification, classification of ace inhibitors and predictions of a receptor antagonist activities. Comp. Biol. Chem., 2003, 27, 217-227.
80. Ponce, Y.M.; Diaz, H.G.; Zaldivar, V.R.; Torrens, F.; Castro, E.A. 3D-chiral quadratic indices of the 'molecular pseudograph's atom adjacency matrix and their application to central chirality codification: classification of ace inhibitors and prediction of a-receptor antagonist activities. Bioorg. Med. Chem., 2004, 12, 5331-5342.
81. Castillo-Garit, J.A., Ponce, Y.M., Torrens, F., García-Domenech, R.; Rodríguez-Borges, J.E. Applications of bond-based 3d-chiral quadratic indices in qsar studies related to central chirality codification. QSAR Comb. Sci., 2009, 28, 1465-1477.
82. Devillers, J.; Balaban, A.T. Eds. In: Topological Indices and Related Descriptors in QSAR and QSPR, Gordon and Breach: Amsterdam, Netherlands, 1999.
83. Todeschini, R.; Consonni, V. In: Medicinal Chemistry, Mannhold, R.; Kubinyi, H.; Timmerman, H. Ed.; Wiley-VCH: Vol. 11, Wein-heim, Germany, 2000.
84. nd Ed., Wiley-VCH, Weinheim, 2009, Vol. 1, pp. 127-135.
85. Balaban, A.T. In: From Chemical Graphs to 3D Modeling. Balaban, A.T. Ed., From Chemical Topology to Three-dimensional Geometry, Plenum Publishing Corporation, New York, 1997, pp. 1-24.
86. Basak, S.C.; Mills, D.; Gute, B.D. Predicting bioactivity and toxicity of chemicals from mathematical descriptors: A chemical-cum-biochemical approach, In: Advances in Quantum Chemistry, D. J. Klein, E. Brandas, Eds., Elsevier, 2011. in press
87. Schultz, H.P.; Schultz, E.B.; Schultz, T.P. Topological Organic Chemistry. 9. Graph Theory and Molecular Topological Indices of Stereoisomeric Organic compounds. J. Chem. Inf. Comput. Sci., 1995, 35, 864-870.
88. de Julian-Ortiz, J.V.; de Alapont, C.G.; Rios-Santamarina, I.; Garcia-Domenech, R.; Galvez, J. Prediction of properties of chiral compounds by molecular topology. J. Mol. Graph. Model., 1998, 16, 14-18.
89. van de Waterbeemd, H.; El Tayar, N.; Testa, B.; Wikström, H.; Largent, B. Quantitative structure-activity relationships and eudis-mic analyses of the presynaptic dopaminergic activity and dopamine D2 and σ receptor affinities of 3-(3-Hydroxyphenyl) piperidi-nes and octahydrobenzo[f]quinolines. J. Med. Chem., 1987, 30, 2175-2181.
90. Lukovits, I.; Linert, W. A Topological account of chirality. J. Chem. Inf. Comput. Sci., 2001, 41, 1517-1520.
91. Pyka, A. A New optical topological Index (Iopt) for predicting the separation of D and L optical isomers by TLC. Part III. J. Planar Chromatogr., 1993, 6, 282-288.
92. Golbraikh, A.; Bonchev, D.; Tropsha, A. Novel chirality descriptors derived from molecular topology. J. Chem. Inf. Comput. Sci., 2001, 41, 147-158.
93. Dinan, L.; Hormann, R.E.; Fujimoto, T. An extensive ecdysteroid CoMFA. J. Comput. Aided Mol. Des., 1999, 13, 185-207.
94. Zheng, W.; Tropsha, A. Novel variable selection quantitative structure-property relationship approach based on the k-nearest-neighbor principle. J. Chem. Inf. Comput. Sci., 2000, 40, 185-194.
95. Golbraikh, A.; Tropsha, A. QSAR modeling using chirality descriptors derived from molecular topology. J. Chem. Inf. Comput. Sci., 2003, 43, 144-154.
96. Cramer, R.D.; Patterson, D.E.; Bunce, J.D. Comparative molecular field analysis (comfa). 1. effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc, 1988, 110, 5959-5967.
97. Marshall, G. R.; Cramer, R. D. Three-dimensional structure-activity relationships. Trends Pharmacol. Sci., 1988, 9, 285-289.
98. Klebe, G.; Abraham, U.; Mietzner, T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J. Med. Chem., 1994, 37, 4130-4146.
99. Wagener, M.; Sadowski, J.; Gasteiger, J. Autocorrelation of molecular surface properties for modeling corticosteroid binding globulin and cytosolic ah receptor activity by neural networks. J. Am. Chem. Soc, 1995, 117, 7769-7775.
100. Silverman, B. D.; Platt, D. E. Comparative molecular moment analysis (CoMMA): 3D-QSAR without molecular superposition. J. Med. Chem., 1996, 39, 2129-2140.
101. Lobato, M.; Amat, L.; Besalu, E.; Carbo-Dorca, R. Structure-Activity relationships of a steroid family using quantum similarity measures and topological quantum similarity indices. Quant. Struct.-Act. Relat., 1997, 16, 465-472.
102. Robert, D.; Amat, L.; Carbo-Dorca, R. Three-dimensional quantitative structure-activity relationships from tuned molecular quantum similarity measures: prediction of the corticosteroid-binding globulin binding affinity for a steroid family. J. Chem. Inf. Comput. Sci., 1999, 39, 333-344.
103. Parretti, M. F.; Kroemer, R. T.; Rothman, J. H.; Richards, W. G. Alignment of molecules by the monte carlo optimization of molecular similarity indices. J. Comput. Chem. 1997, 18, 1334-1353.
104. Maw, H. H.; Hall, L. H. E-State modeling of corticosteroids binding affinity validation of model for small data set. J. Chem. Inf. Comput. Sci., 2001, 41, 1248-1254
105. Besalu, E.; Girones, X.; Amat, L.; Carbo-Dorca, R. Molecular quantum similarity and the fundamentals of QSAR. Acc. Chem. Res., 2002, 35, 289-295.
106. Liu, S.S.; Yin, C.S.; Wang, L.S. Combined MEDV-GA-MLR method for QSAR of three panels of steroids, dipeptides, and COX-2 inhibitors. J. Chem. Inf. Comput. Sci., 2002, 42, 749-756.
107. So, S. S.; Karplus, M. Three-dimensional quantitative structure-activity relationships from molecular similarity matrices and genetic neural networks. 1. method and validations. J. Med. Chem., 1997, 40, 4347-4359.
108. Stiefl, N.; Baumann, K. Mapping property distributions of molecular surfaces: algorithm and evaluation of a novel 3D quantitative structure-activity relationship technique. J. Med. Chem., 2003, 46, 1390-1407.
109. Chen, H.; Zhou, J.; Xie, G. Parm: A genetic evolved algorithm to predict bioactivity. J. Chem. Inf. Comp. Sci., 1998, 38, 243-250.
110. Coats, E.A. The CoMFA steroids as a benchmark dataset for development of 3D QSAR methods. Persp. Drug Discov. Des., 1998, 12(14), 199-213.
111. Cronin, M.T.; Schultz, T.W. Pitfalls in QSAR. J. Mol. Struct., (Theochem) 2003, 622, 39-51.
112. Bucholz, E.; Brown, R. L.; Tropsha, A.; Booth, R. G.; Wyrick, S. D. Synthesis, evolution, and comparative molecular field analysis of 1-phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes as ligands for histamine h1 receptors. J. Med. Chem., 1999, 42, 3041-3054.
113. Perez, C; Pastor, M.; Ortiz, A. R.; Gago, F. Comparative binding energy analysis of hiv-1 protease inhibitors: incorporation of solvent effects and validation as a powerful tool in receptor-based drug design. J. Med. Chem., 1998, 41, 836-852.
114. Holloway, M. K.; Wai, J. M.; Halgren, T. A.; Fitzgerald, P. M. D.; Vacca, J. P.; Dorsey, B. D.; Levin, R. B.; Thompson, W. J.; Chen, L. J.; deSolms, S. J.; Gaffin, N.; Ghosh, A. K.; Giuliani, E. A.; Graham, S. L.; Guare, J. P.; Hungate, R. W.; Lyle, T. A.; Sanders, W. M.; Tucker, T. J.; Wiggins, M.; Wiscount, C. M.; Woltersdorf, O. W.; Young, S. D.; Darke, P. L.; Zugay, J. A. A priori prediction of activity for hiv-1 protease inhibitors employing energy minimization in the active site. J. Med. Chem., 1995, 38, 305-317. HIV.
115. Yang, C; Zhong, C. Chirality factors and their application to QSAR studies of chiral molecules. QSAR Comb. Sci., 2005, 24, 1047-1055.
116. Natarajan, R.; Basak, S.C.; Neumann, T.S. Novel approach for the numerical characterization of molecular chirality. J. Chem. Inf. Model, 2007, 47, 771-775.
117. Kier, L.B.; Hall, L.H. Molecular Structure Description, Academic Press: New York, 1999; pp. 13-36.
118. Klun, J.A.; Schmidt, W.F.; Debboun, M. Stereochemical effects in an insect repellent. J. Med. Entomol, 2001, 38, 809-812.
119. Mills, J.A.; Klyne, W. Progress in Stereochemistry, Butterworths: London, 1954, pp. 204-212.
120. Randic, M.; Razinger, M. On characterization of molecular shapes. J. Chem. Inf. Comput. Sci., 1995, 35, 594-606.
121. Randic, M.; Razinger, M. Molecular shapes and chirality. J. Chem. Inf. Comput. Sci., 1996, 36, 429-442.
122. Randic, M. Graph theoretical descriptors for two-dimensional chirality with possible extension to three-dimensional chirality. J. Chem. Inf. Comput. Sci., 2001, 41, 639-649.
123. Moreau, G. Atomic chirality, a quantitative measure of the chirality of the environment of an atom. J. Chem. Inf. Comput. Sci., 1997, 37, 929-938.
124. Wildman S. A.; Crippen, G. M. Validation of DAPPER for 3D QSAR: conformational search and chirality metric. J. Chem. Inf. Comput. Sci., 2003, 43, 629-636.
125. Wildman, S.A; Crippen, G.M. Three-dimensional Molecular Descriptors and a Novel QSAR Method. J. Mol. Graph. Model, 2002, 21, 161-170.
126. Hansch, C.A.; Hathaway, B.A.; Guo, Z.R.; Selassie, CD.; Dietrich, S.W.; Blaney, J.M.; Langridge, R.; Volz, K.W.; Kaufman, B.T. Crystallography, Quantitative Structure-activity relationships, (QSAR) and molecular graphics in a comparative analysis of the inhibition of dihydrofolate reductase from chicken liver and lacto-bacillus casei by 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(substituted-phenyl)-s-triazines. J. Med. Chem., 1984, 27, 129-143.
127. Hansch, C.A.; Li, R.L.; Blaney, J.M.; Langridge, R. Comparison of the inhibition of escherichia coli and lactobacillus casei dihydrofolate reductase by 2,4-diamino-5-(substituted-benzyl)pyrimidines: quantitative structure-activity relationships, x-ray crystallography, and computer graphics in structure-activity analysis. J. Med. Chem., 1982, 25, 777-784.
128. Selassie, CD.; Fang, Z.; Li, R.; Hansch, C; Debnath, G.; Klein, T.L.; Langridge, R.; Kaufman, B.T. On the structure selectivity problem in drug design. a comparative study of benzylpyrimidine inhibition of vertebrate and bacterial dihydrofolate reductase via molecular graphics and quantitative structure-activity relationships. J. Med. Chem., 1989, 32, 1895-1905.
129. Mayer, D.; Naylor, C.B.; Motoc, I.; Marshall, G. R. A Unique geometry of the active site of angiotensin-converting enzyme consistent with structure-activity studies. J. Comput.-Aided Mol. Des., 1987, 1, 3-16.
130. Cho, S.J.; Garsia, M.L.S.; Bier, J.; Tropsha, A. Structure-based alignment and comparative molecular field analysis of acetylcho-linesterase inhibitors. J. Med. Chem., 1996, 39, 5064-5071.
131. Kuz'min, V.E.; Muratov, E.N.; Artemenko, A.G.; Varlamova, E.V.; Gorb, L.; Wang, J.; Leszczynski, J. Consensus QSAR modeling of phosphor-containing chiral AChE inhibitors. QSAR Comb. Sci., 2009, 28, 664-677.
132. 2! J. Mol. Graph. Model., 2002, 20, 269-276.
133. Ruch, E. Chiral derivatives of achiral molecules: standard classes and the problem of right-left classification. Angew. Chem. Int. Ed., 1972, 16, 65-72.
134. King, R.B. Chirality and handedness: the Ruch "Shoe-Potato" dichotomy in the right-left classification problem. Ann. N.Y. Acad. Sci., 2003, 988, 158-170.
135. Fowler, P.W. Quantification of chirality: attempting the impossible. Symmetry, Culture Sci., 2003, 16, 321-334.
136. Mesecar, A.D.; Koshland D.E. A New model for protein stereo-specificity. Nature, 2000, 403, 614-615.